Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221839 | 0.76 | MAPT (0.47) | MAPTKDM4EPOLBMAPK1VCAM1 | |
| SCHEMBL645817 | 0.76 | VCAM1 (0.55) | MAPTKDM4EPOLBMAPK1VCAM1 | |
| SCHEMBL5217141 | 0.74 | NOS1 (0.48) | MAPTKDM4EPOLBMAPK1VCAM1 | |
| SCHEMBL70813 | 0.72 | MAPT (0.63) | MAPTKDM4EPOLBMAPK1VCAM1 | |
| SCHEMBL30159180 | 0.72 | MAPT (0.52) | MAPTKDM4EPOLBMAPK1VCAM1 | |
| SCHEMBL22081923 | 0.72 | MAPT (0.52) | MAPTKDM4EPOLBMAPK1VCAM1 | |
| SCHEMBL24036773 | 0.72 | NPC1 (0.42) | MAPTKDM4EPOLBLMNAMAP2K4 | |
| SCHEMBL5217731 | 0.71 | MAPT (0.47) | MAPTKDM4EPOLBMAPK1VCAM1 | |
| SCHEMBL989006 | 0.71 | VCAM1 (0.56) | MAPTKDM4EPOLBMAPK1VCAM1 | |
| SCHEMBL5924211 | 0.71 | ESR1 (0.57) | MAPTKDM4EPOLBVCAM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE CORP (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4431098-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE Corporation (JP) | 2024-09-18 | — | — | EP | disclosed |
| CN-115551846-B | 1,4,5, 6-tetrahydropyrimidin-2-amine derivatives | ＵＢＥ株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
| EP-4151632-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE Corporation (JP) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551846-A | 1,4,5,6-tetrahydropyrimidin-2-amine derivatives | ＵＢＥ株式会社 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | MAPT 3157/4885KDM4E 1887/4885POLB 860/4885 |
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | CYP21A2, HSD11B2, MC2R | MAPT 2014/4885KDM4E 4332/4885POLB 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.